Comparative Pharmacology
Head-to-head clinical analysis: GENTACIDIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTACIDIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE.
GENTACIDIN vs NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Neomycin and polymyxin B sulfates are aminoglycoside and polypeptide antibiotics, respectively, that inhibit bacterial protein synthesis and disrupt bacterial cell membrane integrity. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
5-7 mg/kg IV every 24 hours.
Ophthalmic: 1-2 drops in affected eye(s) every 3-4 hours; severe infections: 1-2 drops every 1-2 hours, then taper. Otic: 3-4 drops in affected ear(s) 3-4 times daily.
None Documented
None Documented
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
Neomycin: 2-3 hours (IM/IV, if absorbed); Polymyxin B: 6-7 hours; Dexamethasone: 3-4.5 hours. Clinically, neomycin's half-life is not relevant due to minimal absorption; polymyxin B prolonged in renal impairment; dexamethasone CNS effect lasts > half-life.
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Neomycin: ~99% of oral dose eliminated unchanged in feces; <1% absorbed renally excreted. Polymyxin B: ~60% renal elimination of absorbed fraction; remainder non-renal via biliary/fecal. Dexamethasone: ~65% renal as metabolites, <10% unchanged; ~35% fecal.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic